Thursday, September 29, 2016
$40 Million Approved for Meningitis Outbreak Victims
By Walter F. Roche Jr.
The U.S. Department of Justice has approved a $40 million grant request that will go into a fund to benefit victims of the 2012 fungal meningitis outbreak and victims can begin applying to the Massachusetts Attorney General whose office is administering the fund.
Information on the grant approval and the application procedure were disclosed Thursday in separate announcements.
U.S. Rep. Mike Bishop, a Michigan Republican, whose district was particularly hard hit in the outbreak disclosed that the application for the $40 million had been approved. The grant will go to the Massachusetts Attorney General's office which had applied for the funds.
Chloe Gotsis, a spokeswoman for the Attorney General said a special division will be set up to handle grant applications.
To be eligible victims must either be on an official victims' list compiled by the Federal Bureau of Investigation or the U.S. Attorney's office in Boston, Mass. which conducted the criminal investigation of the outbreak.
Gotsis said her office will not be making separate eligibility determinations
Applicants can fill out the needed forms online at the Attorney General's office.
( learn how to apply for compensation at this link)
"I am grateful for the work of the DOJ and my House colleagues in our fight for justice," Bishop said in announcing the approval.
"These families have gone through unimaginable heartache losing loved ones, caring for the sick and facing financial uncertainty for the last four years," Bishop added.
The $40 million will come from a national fund for victims of crimes, which is comprised of fines and assessments on defendants sued or prosecuted by DOJ.
Fifteen of the 19 Michigan victims of the outbreak who died, lived in Bishop's district. Nationwide 77 patients died out of the 778 who were sickened.
Contact: wfrochejr999@gmail.com
Wednesday, September 28, 2016
Attorney Outbreak Suit Expenses Listed
Expenses being sought by attorneys in the settlement of the 2012 fungal meningitis outbreak total just under $900,000 and include meal and lodging expenses totaling some $237,998.
Details of the expense reimbursements being sought were included in filings for legal fees totaling more than $12.4 million that were filed this week in U.S. District Court in Boston, Mass.
The filings show that requested expense reimbursements actually topped $1 million but were then reduced downward by $192,494.16.
Airfare requested totaled $212,11.76, that total run up as lawyers traveled from around the country to court sessions in Boston, Mass.
The top expense category was fees paid for professional services, such as accounting or testing, which totaled $431,206.46
Here is a list of expenses finally approved versus amounts requested in three categories:
Firm Approved Requested Meals Requested Lodging Requested Air Fare
Andrews Thornton $43,631.41 $687.03 $22,362.41 $47,416.11
Bransetter Stranch $174,237.70 $28,915.72 $42,053.48 $50,096.75
Clayton $4,121.53 $31.99 $1,263.44 $2,826.19
Cohen Placitella $0.00 $0.00 $0.00 $0.00
Crandall Law $89,676.06 $4,850.79 $24,914.15 $22,492.70
Ellis & Rapacki $62,645.51 $326.25 $1,568.70 $2,091.40
Fay $5,000 $0.00 $0.00 $0.00
Federman $77.04 $0.00 $0.00 $0.00
Galligan $20,064.44 $0.00 $14,576.49 $0.00
Hagens $84,610.11 $6,317.72 $5,277.99 $8,902.20
JJS * $53,804.47 $2,099.91 $1,528.70 $4,701.35
LHCB * $169,071 $18,922.71 $31,591.22 $35,732.54
Leader Nolan $39,519.12 $679.21 $4,013.59 $5,936.58
Lipton $37,272.95 $2,121.28 $3,651.78 $11,572.58
Miller Law $40,638.17 $329.93 $2,100.02 $2,602.70
Oliver Law $5,278.96 $648.88 $233.66 $812.88
Shef $5,000 $0.00 $0.00 $0.00
SMBB * $2440.01 $29 $1,779.11 $632
M. Wright $32,772.50 $1,083.16 $11,409.21 $1,861.79
Zamora $29,309.04 $0.00 $2,594.13 $3,467.60
*JJS Janet Jenner and Suggs
*LHCB Leiff Cabreser
*SMBB Saltz Mongeluzzi
Judge Approves First Outbreak Payments to Victims' Survivors
By Walter F. Roche Jr.
U.S. District Judge Rya Zobel today approved the first two awards to come before her for the survivors of patients who died in the 2012 fungal meningitis outbreak caused by a Massachusetts drug compounder.
Zobel's approval came during a session in her Boston, Mass. courtroom, on petitions submitted by the the attorney representing both families. Her approval was necessary under Virginia's wrongful death statute.
The three survivors of one victim will share $169,651.92, while the three survivors of the second victim will share $469,964.49.
The payments are coming from funds totaling some $210 million amassed in the aftermath of the outbreak caused by fungus tainted steroids shipped to health providers across the country by the New England Compounding Center.
About $120 million of the total came from settlements in NECC's bankruptcy and additional funding came from settlements with health care providers who injected patients with the fungus laden steroids.
The total award in one case approved today by Zobel was for $805,622.88 with 40 percent going to attorney J. Scott Sexton, $12,182 going to legal and other expenses, leaving $156,654.83 going to each of the three beneficiaries.
In the second case the total award was $290,786.77, with attorneys fees totaling $116,314.71, other expenses $4,801.18, leaving $169,651.92 to be split between the three survivors in shares of $56,550.54 each. The victim in the case died in October of 2012.
Both victims were injected with methylprednisolone acetate from NECC and administered at Insight Health, which is contributing $40 million of the $210 million total.
Additional payments could come at a later date from the NECC bankruptcy settlement.
Other payments, not requiring court approval, are being made by the attorney appointed as trustee of the payment funds, Lynne Riley. She has stated that checks began to be mailed some two to three weeks ago.
The outbreak sickened 778 patients, killing 77 of them.
Contact: wfrochejr999@gmail.com
Tuesday, September 27, 2016
Lawyers Seek $12.4 Million in Fees, Expenses
By Walter F. Roche Jr.
A team of lawyers that litigated and negotiated for a multimillion settlement in the wake of a deadly fungal meningitis are asking a federal judge to approve nearly $12.5 million in fees and expenses or 8 percent of the total recovery.
In a massive filing today in U.S. District Court in Boston, Mass., the panel of lawyers said the fees were justified and that all parties would be receiving less than they originally sought.
Calling the results of their efforts "quite extraordinary," the filing by lead attorney Thomas Sobol recounted the long history of the outbreak beginning with the discovery in the Fall of 2012 that a deadly fungal meningitis outbreak was spreading across the country.
The fees, if approved, will come out of a national recovery fund now estimated at $130.1 million, but could grow to an estimated $157.35 million.
The fees sought in the petition are intended for services that benefited all those seeking claims and is called a "common benefit fund." The fees are in addition to fees victims will be obligated to pay their individual attorneys.
According to the filings fees paid to individual lawyers under the proposal range from $275 to $550 an hour. The largest single allocation, $2.6 million in fees and expenses would go to Sobol's firm, Hagens,Berman Sobol and Shapiro
Sobol noted in the filing that it is not expected that any of the fees will be approved until near the end of the calendar year and after victims of the outbreak receive their initial payments from the national settlement fund.
Checks for individual claims have now begun to trickle in to lawyers across the country. Nashville attorney William Leader said today his firm has now received the first check for one of its clients.
Sobol noted that an 8 percent fee already had won initial approval from U.S. District Judge Rya Zobel who has been presiding over 379 of cases stemming from the outbreak blamed on fungus laden steroids shipped from the now defunct New England Compounding Center in Framingham, Mass.
"All counsel are receiving less than their reported or allocated lodestar," the petition states, noting that original fee requests totaled $14.7 million, rather than the $12.4 million being submitted for approval.
Acknowledging that the total fund was "Insufficient to fully compensate claimants given the enormity of the wrongs committed here," Sobol acknowledged that some firms "may not be happy with our suggestions. These are compromises."
"If there is dissent it will be only by a few firms," Sobol wrote.
Objections must be filed by Oct. 24.
According to the filing the major allocations for fees and expenses will go to the following law firms:
Hagens Berman Sobol and Shapiro 8,645 hours $2,610,662
Branstetters Stranch and Jennings 3,899 hours $1,509,843
Crandall and Katt 1,760 hours $898,997
Janet Jenner and Suggs $1,075,737
Lief Cabraser Heiman and Bernstein $1,023,554
Lipton Law $534,602
Orlando Firm LLC $572,557
Andrews and Thornton $474,051
Cohen Placitella and Roth $417,883
Ellis and Rapacki $1,608,813
Collins Gilbert Wright and Carter $153,855
Leader, Bulso and Norton $221,073
Kinnard Clayton $81,506
Miller Law Firm $646,299
Riley Williams and Piatt $121,186
Saltz Mongeluzzi $113,283
Sommers Schwartz $125,365
Lawyers Seek $12.4 Million in Fees, Expenses
By Walter F. Roche Jr.
A team of lawyers that litigated and negotiated for a multimillion settlement in the wake of a deadly fungal meningitis are asking a federal judge to approve nearly $12.5 million in fees and expenses or 8 percent of the total recovery.
In a massive filing today in U.S. District Court in Boston, Mass., the panel of lawyers said the fees were justified and that all parties would be receiving less than they originally sought.
Calling the results of their efforts "quite extraordinary," the filing by lead attorney Thomas Sobol recounted the long history of the outbreak beginning with the discovery in the Fall of 2012 that a deadly fungal meningitis outbreak was spreading across the country.
The fees, if approved, will come out of a national recovery fund now estimated at $130.1 million, but could grow to an estimated $157.35 million.
The fees sought in the petition are intended for services that benefited all those seeking claims and is called a "common benefit fund." The fees are in addition to fees victims will be obligated to pay their individual attorneys.
According to the filings fees paid to individual lawyers under the proposal range from $275 to $550 an hour.
Sobol noted in the filing that it is not expected that any of the fees will be approved until near the end of the calendar year and after victims of the outbreak receive their initial payments from the national settlement fund.
Checks for individual claims have now begun to trickle in to lawyers across the country. Nashville attorney William Leader said today his firm has now received the first check for one of its clients.
Sobol noted that an 8 percent fee already had won initial approval from U.S. District Judge Rya Zobel who has been presiding over 379 of cases stemming from the outbreak blamed on fungus laden steroids shipped from the now defunct New England Compounding Center in Framingham, Mass.
"All counsel are receiving less than their reported or allocated lodestar," the petition states, noting that original fee requests totaled $14.7 million, rather than the $12.4 million being submitted for approval.
Acknowledging that the total fund was "Insufficient to fully compensate claimants given the enormity of the wrongs committed here," Sobol acknowledged that some firms "may not be happy with our suggestions. These are compromises."
"If there is dissent it will be only by a few firms," Sobol wrote.
Objections must be filed by Oct. 24.
According to the filing the major allocations will go to the following law firms:
Hagens Berman Sobol and Shapiro 8,645 hours
Branstetters Stranch and Jennings 3,899 hours
Crandall and Katt 1,760 hours
Janet Jenner and Suggs
Lief Cabraser Heiman and Bernstein
Lipton Law
Orland Firm LLC
Andrews and Thornton
Cohen Placiteller and Roth
Ellis and Rapacki
Judge Upholds NECC Conspiracy Charges
By Walter F. Roche Jr.
A federal judge in Boston, Mass. has denied a motion to dismiss conspiracy charges against several of the criminal defendants in the case against former owners and employees of the company blamed for a deadly fungal meningitis outbreak.
In an 11-page decision, U.S. District Judge Richard Stearns said the indictment issued by a grand jury in late 2013 contained sufficient information to allow the defendants to attempt to rebut the charges.
The motion was filed in behalf of Barry Cadden, Gregory Conigliaro, Alla Stepanets, Sharon Carter and Robert Ronzio, all tied to the New England Compounding Center, the company blamed for the 2012 fungal meningitis outbreak.
The challenged section of the indictment charged the defendants with engaging in a conspiracy to defraud the U.S. Food and Drug Administration by inducing "regulatory authorities, including the FDA, into believing that NECC was doing busines as a compounding pharmacy when in fact it was in the business of manufacturing drugs."
Stearns said that based on the law and existing precedents the government did not have to show the fraud was financial.
"Count Three clearly satisfies the pleading requirements," Stearns wrote, noting that the indictment included allegations that NECC submitted false names and made other efforts to obstruct a state investigation of their operations.
Cadden, a founder and part owner of the defunct Framingham, Mass, company is scheduled to go on trial in January along with chief pharmacist Glenn Chin. The other defendants face a March 2017 trial date.
Charges against Cadden and Chin include 25 counts of second degree murder.
The outbreak, caused by fungus laden steroids from NECC, sickened 778 patients across the country, killing 77 of them.
Contact: wfrochejr999@gmail.com
Thursday, September 22, 2016
Massive Sterile Drug Recall in Progress
Wells Pharmacy Network Issues Voluntary Nationwide Recall of Sterile Products due to Concern for Lack of Sterility Assurance
For Immediate Release
September 20, 2016
Contact
Announcement
Administration of a drug product intended to be sterile that has microbial contamination may result in infections that may be serious and life-threatening.
The recalled products were used for a variety of indications. NO VIAL OR PORTION OF ANY LOT OF THESE MEDICATIONS HAS BEEN FOUND TO BE NON STERILE. All recalled products have a label that includes the name Wells Pharmacy Network, logo, drug name, and expiration date. If unsure, Customers can call the pharmacy to determine if their product is on the list. To date, no adverse events have been reported.
WPN takes the utmost care to ensure patient safety. All patients and providers that received any sterile compounded products prepared between February 22, 2016 and September 14, 2016, and that remain within expiry, should take the following actions:
- Discontinue use of the products;
- Quarantine any unused product until further instructions are received on how to return the product; and
- Contact WPN at the Quality hotline at (800) 794-2360 Monday through Friday, between 9:00 am and 6:00 pm EST or email at WPNQuality@wellsrx.com to discuss the return of any unused sterile product.
Adverse reactions or quality problems experienced with the use of these products in humans or animals may be reported to FDA in the following ways:
- For adverse
events in Humans please use FDA’s MedWatch Adverse Event Reporting
program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
- For reporting animal adverse drug events, please follow the link to the FORM FDA 1932a found at: http://www.fda.gov/AnimalVeterinary/SafetyHealth/ReportaProblem/ucm055305.htm
Again, WPN’s primary concern is your safety and WPN is taking this action out of an abundance of caution. Thank you for your support.
List of products to be recalled:
| Drug | Lot # | Animal Type |
|---|---|---|
| TESTOSTERONE CYPIONATE IN SESAME OIL (1ML) 200MG/ML INJECTABLE | 03282016@10 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (1ML) 200MG/ML INJECTABLE | 03282016@16 | Human |
| ULTRA-TEST 250 (CYP 80%/PROP 20%) 250MG/ML INJECTABLE | 03282016@22 | Human |
| TESTOSTERONE ENANTHATE-GRAPESEED OIL 200MG/ML INJECTABLE | 03282016@3 | Human |
| TESTOSTERONE CYPIONATE IN SESAME OIL 200MG/ML INJECTABLE | 03282016@6 | Human |
| QUAD3 (2ML) 30MG/3MG/30MCG/0.1MG/ML INJECTABLE | 03292016@12 | Human |
| PHENYLEPHRINE HCL - (5ML) 1MG/ML (0.1%) INJECTABLE | 03292016@3 | Human |
| MIC COMBO - STANDARD (30ML) 15MG/50MG/100MG/ML INJECTABLE | 03292016@5 | Human |
| NICOTINAMIDE ADENINE DINUCLEOTIDE (NADH) - LYOPHILIZED (P.F.) 100MG INJECTABLE | 03302016@13 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (1ML) 200MG/ML INJECTABLE | 03302016@4 | Human |
| ULTRA-TEST 200 (8ML) GRAPESEED OIL (CYP 90%/PROP 10%) 200MG/ML INJECTABLE | 03302016@5 | Human |
| TESTOSTERONE ENANTHATE-GRAPESEED OIL 200MG/ML INJECTABLE | 03302016@6 | Human |
| METHIONINE/INOSITOL/CHOLINE/CHROMIUM+B12(M) - 10ML 25MG/50MG/50MG/25MCG/1MG/ML INJECTABLE | 03302016@8 | Human |
| METHIONINE/INOSITOL/CHOLINE/B-COMP+CARN+LIDO (30ML) 15MG/30MG/30MG/85MG/20MG/ML INJECTABLE | 03302016@9 | Human |
| CHORIONIC GONADOTROPIN, LYOPHILIZED (HCG) 11,000 UNIT VIAL VIAL | 03312016@1 | Human |
| ALPROSTADIL - (5ML) 20MCG/ML INJECTABLE | 03312016@6 | Human |
| TRIMIX - (10ML) 30MG / 2MG / 20MCG INJECTABLE | 03312016@7 | Human |
| QUAD2 (5ML) 9MG/1MG/10MCG/0.1MG/ML INJECTABLE | 03312016@8 | Human |
| TESTOSTERONE CYPIONATE IN SESAME OIL (10ML) 210MG/ML INJECTABLE | 03312016@9 | Human |
| TESTOSTERONE CYPIONATE/ZINC SULFATE IN GRAPESEED 200MG/200MCG/ML INJECTABLE | 04012016@2 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (3ML) 200MG/ML INJECTABLE | 04012016@4 | Human |
| BIMIX - (5ML) 30MG/1MG INJECTABLE | 04012016@7 | Human |
| TITAN UP (INOS/CHOL/LEUC/CARN/CHROM/LIDO) 25MG/25MG/1.5MG/25MG/25MCG/10MG INJECTABLE | 04012016@9 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (1ML) 200MG/ML INJECTABLE | 04042016@10 | Human |
| TESTOSTERONE PROPIONATE 100MG/ML INJECTABLE | 04042016@2 | Human |
| TRIMIX WITH ATROPINE (2ML) 30MG/3MG/150MCG/0.2MG/ML INJECTABLE | 04042016@22 | Human |
| CHORIONIC GONADOTROPIN, LYOPHILIZED (HCG) 11,000 UNIT VIAL VIAL | 04042016@30 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (5ML) 200MG/ML INJECTABLE | 04042016@7 | Human |
| METHYLCOBALAMIN - 30ML 1,000MCG/ML INJECTABLE | 04052016@1 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (1ML) 50MG/ML INJECTABLE | 04052016@4 | Human |
| METHIONINE/INOSITOL/CHOLINE/B-COMPLEX - (30ML) 15MG/50MG/100MG/ML INJECTABLE | 04052016@5 | Human |
| MITOMYCIN, LYOPHILIZED (BUFFERED) 40MG INJECTABLE | 04062016@106 | Human |
| SERMORELIN ACETATE/GHRP (2) 6MG/4.5MG KIT | 04062016@170 | Human |
| LEUCINE/ISOLEUCINE/VALINE 10MG/10MG/5MG/ML INJECTABLE | 04062016@3 | Human |
| SODIUM BICARBONATE, MDV 8.4% INJECTABLE | 04062016@4 | Human |
| METHYLCOBALAMIN - 10ML 1,000MCG/ML INJECTABLE | 04062016@5 | Human |
| HISTRELIN ACETATE, LYOPHILIZED 5.5MG INJECTABLE | 04062016@6 | Vet |
| CHORIONIC GONADOTROPIN, LYOPHILIZED (HCG) 5,000 UNIT VIAL VIAL | 04062016@7 | Human |
| TRI1 - NR (2ML) 3.6MG/0.4MG/0.04MG INJECTABLE | 04072016@10 | Human |
| TRIMIX - (10ML) 30MG / 1MG / 10MCG INJECTABLE | 04072016@13 | Human |
| METHIONINE/INOSITOL/CHOLINE/B-COMP+CARN+LIDO (30ML) 15MG/30MG/30MG/85MG/20MG/ML INJECTABLE | 04072016@15 | Human |
| SERMORELIN ACETATE/GHRP (2) & (6) 9MG/9MG/9MG KIT | 04072016@19 | Human |
| QUAD4 (2ML) 30MG/3MG/60MCG/0.2MG/ML INJECTABLE | 04072016@8 | Human |
| TESTOSTERONE CYPIONATE IN SESAME OIL (1ML) 200MG/ML INJECTABLE | 04072016@85 | Human |
| METHIONINE/INOSITOL/CHOLINE/B-COMPLEX - (30ML) 15MG/50MG/100MG/ML INJECTABLE | 04082016@3 | Human |
| METHIONINE/INOSITOL/CHOLINE/B-COMP/(M)/CHROMIUM/CARNITINE 20MG/40MG/50MG/25MCG/25MG/ML INJECTABLE | 04082016@4 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (10ML) 200MG/ML INJECTABLE | 04082016@6 | Human |
| PROGESTERONE IN SESAME OIL 150MG/ML INJECTABLE | 04082016@7 | Vet |
| QUAD3 (5ML) 30MG/3MG/30MCG/0.1MG/ML INJECTABLE | 04112016@10 | Human |
| TRIMIX WITH ATROPINE (10ML) 30MG/3MG/150MCG/0.2MG/ML INJECTABLE | 04112016@13 | Human |
| NANDROLONE DECANOATE (H) 200MG/ML INJECTABLE | 04112016@16 | Human |
| VITAMIN D3 IN SESAME OIL (5ML) 100,000 IU/ML INJECTABLE | 04112016@23 | Human |
| TRIMIX / ATROPINE (10ML) 30MG/3MG/60MCG/0.2MG/ML INJECTABLE | 04112016@6 | Human |
| TRI2 - NR (5ML) 30MG/3MG/0.3MG INJECTABLE | 04112016@8 | Human |
| TESTOSTERONE CYPIONATE/ANASTROZOLE 200MG/1MG/ML INJECTABLE | 04122016@1 | Human |
| QUAD1 (2ML) 0.9MG/0.2MG/20MCG/0.01MG/ML INJECTABLE | 04122016@17 | Human |
| TRIMIX (10ML) 30MG/3MG/100MCG INJECTABLE | 04122016@18 | Human |
| TRI1 - NR (5ML) 3.6MG/0.4MG/0.04MG INJECTABLE | 04122016@19 | Human |
| TESTOSTERONE CYPIONATE IN SESAME OIL 200MG/ML INJECTABLE | 04122016@2 | Human |
| TRI-TEST 200 (CEP) 200MG/ML INJECTABLE | 04122016@4 | Human |
| MIC COMBO - STANDARD (30ML) 15MG/50MG/100MG/ML INJECTABLE | 04122016@76 | Human |
| TESTOSTERONE ENANTHATE-GRAPESEED OIL 200MG/ML INJECTABLE | 04132016@1 | Human |
| TITAN UP (INOS/CHOL/LEUC/CARN/CHROM/LIDO) 25MG/25MG/1.5MG/25MG/25MCG/10MG INJECTABLE | 04132016@14 | Human |
| INOSITOL/CHOLINE/B-COMP+LEUCINE+CARN+CHROM+LIDO 25MG/25MG/1.5MG/25MG/25MCG/10MG INJECTABLE | 04132016@32 | Human |
| DMSO W/LIDOCAINE 50%/0.5% SOLUTION | 04132016@69 | Human |
| TITAN UP (INOS/CHOL/LEUC/CARN/CHROM/LIDO) 25MG/25MG/1.5MG/25MG/25MCG/10MG INJECTABLE | 04132016@8 | Human |
| CHORIONIC GONADOTROPIN, LYOPHILIZED (HCG) 3,500 UNIT VIAL VIAL | 04132016@91 | Human |
| CHORIONIC GONADOTROPIN, LYOPHILIZED (HCG) 20,000 UNIT VIAL VIAL | 04132016@96 | Human |
| MITOMYCIN SOLUTION, STERILE 0.02% (200MCG/ML) OPHTHALMIC | 04142016@107 | Human |
| METHYLCOBALAMIN - 30ML 1,000MCG/ML INJECTABLE | 04142016@112 | Human |
| QUAD1 (2ML) 0.9MG/0.2MG/20MCG/0.01MG/ML INJECTABLE | 04142016@14 | Human |
| QUAD1 (5ML) 0.9MG/0.2MG/20MCG/0.01MG/ML INJECTABLE | 04142016@15 | Human |
| QUAD4 (5ML) 30MG/3MG/60MCG/0.2MG/ML INJECTABLE | 04142016@16 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (10ML) 200MG/ML INJECTABLE | 04142016@2 | Human |
| SERMORELIN ACETATE 28MG KIT | 04142016@28 | Human |
| CHORIONIC GONADOTROPIN, LYOPHILIZED (HCG) 6,000 UNIT VIAL VIAL | 04142016@34 | Human |
| SERMORELIN ACETATE 15MG KIT | 04142016@43 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (5ML) 20MG/ML INJECTABLE | 04142016@5 | Human |
| TESTOSTERONE CYPIONATE IN GRAPE SEED OIL (5ML) 100MG/ML INJECTABLE | 04142016@7 | Human |
| SERMORELIN ACETATE/GHRP (2) 9MG/3MG KIT | 04152016@149 | Human |
| ULTRA-TEST 200 - (10ML VIAL) 200MG/ML INJECTABLE | 04152016@2 | Human |
| SERMORELIN ACETATE/GHRP (2) 9MG/9MG KIT | 04152016@21 | Human |
| METHYLCOBALAMIN 5,000MCG/ML INJECTABLE | 04152016@3 | Human |
| METHIONINE/INOSITOL/CHOLINE/CHROMIUM+B12(M) - 10ML 25MG/50MG/50MG/25MCG/1MG/ML INJECTABLE | 04152016@5 | Human |
| MITOMYCIN, LYOPHILIZED (BUFFERED) 40MG INJECTABLE | 04182016@10 | Human |
| TESTOSTERONE CYPIONATE IN SESAME OIL 200MG/ML INJECTABLE | 04182016@33 | Human |
| METHIONINE/INO |
Subscribe to:
Posts (Atom)